Welcome to our dedicated page for Galera Therapeutics SEC filings (Ticker: GRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Galera Therapeutics, Inc. (GRTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on Galera’s clinical-stage biopharmaceutical activities, financial condition, strategic decisions, and changes in trading status.
Galera’s periodic reports, such as Forms 10-K and 10-Q referenced in its press releases, discuss its focus on developing novel, proprietary therapeutics related to radiotherapy and cancer, including historical work on superoxide dismutase mimetics and more recent emphasis on a pan-nitric oxide synthase inhibitor in advanced breast cancer. These filings typically describe research and development expenses, general and administrative costs, net losses, cash and cash equivalents, and risk factors associated with funding needs, regulatory uncertainty, and potential cessation of operations.
Current reports on Form 8-K are especially important for tracking material events. For example, an October 2025 Form 8-K details an Asset Purchase and Sale Agreement under which Biossil Inc. agreed to acquire all of Galera’s right, title, and interest in assets related to avasopasem, rucosopasem, and other dismutase mimetic assets, and to assume related obligations under a royalty agreement, in exchange for an upfront payment and potential future milestone and contingent value right payments. Another Form 8-K notes that Galera’s common stock trades on the OTCQB Market under the symbol GRTX.
Earlier disclosures referenced in company communications include information about the Board’s approval of a Plan of Liquidation and Dissolution, adoption of a limited duration stockholder rights agreement, workforce reductions, and the engagement of financial advisors to review strategic alternatives. Together, these filings document Galera’s transition from a Nasdaq-listed clinical-stage oncology company through strategic review, proposed dissolution, acquisition of Nova Pharmaceuticals, and sale of key assets.
On Stock Titan, AI-powered tools can help interpret Galera’s filings by summarizing complex sections of Forms 10-K and 10-Q, highlighting key terms in material agreements disclosed on Form 8-K, and organizing information about trading status and corporate actions. This allows readers to quickly understand how regulatory filings relate to Galera’s evolving business and the GRTX stock.
Emerald Bioventures, LLC and Timothy Opler report beneficial ownership of 40,216,160 shares of Galera Therapeutics common stock, representing approximately 26.5% of the class. This stake reflects Nova Pharmaceuticals merger consideration, a December 2024 private placement, and a partial mandatory conversion of Series B preferred stock.
Emerald bought 3,057,973 Galera common shares for about $199,991 in the December 2024 private placement and received Series B Non-Voting Convertible Preferred Stock in the Nova merger. On April 7, 2026, 37,158.1873807108 Series B shares converted into 37,158,187 common shares, leaving 20,813.8186192892 Series B shares, which are not yet convertible without shareholder approval.
Emerald and other insiders entered stockholder support agreements covering about 51.1% of Galera’s outstanding capital stock to vote in favor of Galera’s planned merger with Obsidian Therapeutics and related transactions. The filing states the position is held for investment, while preserving flexibility to buy or sell Galera securities over time.
Galera Therapeutics, Inc. disclosed a proposed merger agreement dated April 14, 2026 under which Galera and Obsidian Therapeutics will combine into a newly-formed parent, with Galera and Obsidian each becoming wholly owned subsidiaries of the parent following the Galera Merger. The companies said the combined entity will file a registration statement on Form S-4 containing a proxy statement/prospectus and that materials will be mailed to Galera stockholders.
The filing also includes an Obsidian press release announcing an oral presentation of Phase 2 OBX-115 data in advanced melanoma at the 2026 ASCO Annual Meeting (May 29–June 2, 2026). The release describes OBX-115 as an engineered TIL therapy armored with membrane-bound IL15 and references ongoing Phase 1/2 Agni-01 (NCT06060613) clinical development.
Galera Therapeutics disclosed a pending merger with Obsidian Therapeutics under an Agreement and Plan of Merger dated April 14, 2026, pursuant to which Galera and Obsidian will each merge into newly formed subsidiaries of Gazelle Parent, Inc.
The companies say a registration statement on Form S-4 (including a proxy statement/prospectus) will be filed and mailed to Galera stockholders; additional SEC filings and a concurrent private placement financing are referenced.
Galera Therapeutics is holding a combined 2025–2026 virtual annual meeting on May 8, 2026 to elect directors, ratify its auditor, hold advisory say‑on‑pay votes, and approve several charter amendments.
Stockholders will vote on increasing authorized common stock from 200 million to 400 million shares, allowing action by written consent, and authorizing a reverse stock split at a ratio between 1:75 and 1:200. These changes are designed in part to support a planned all‑stock merger with Obsidian Therapeutics and a concurrent $350 million private placement that is expected to fund the combined company into the second half of 2028 and through key 2027 clinical milestones. As of April 10, 2026, Galera had 160,429,783 common shares outstanding and 39,373,206 shares reserved under options, RSUs and warrants.
Galera Therapeutics and Obsidian Therapeutics entered a definitive all‑stock merger agreement to form a newly formed company expected to operate as Obsidian Therapeutics, Inc., and to apply to list on Nasdaq under the ticker OBX. The companies have secured commitments for an oversubscribed private placement expected to raise $350 million that is planned to close immediately prior to the merger.
The combined company’s cash and cash equivalents at closing, including the private placement, is anticipated to provide runway into the second half of 2028, supporting Obsidian’s lead product OBX‑115 through key clinical readouts: Phase 1 NSCLC data expected in H1 2027 and melanoma topline data by year‑end 2027. Under the merger terms, pre‑closing Galera stockholders (excluding private placement participants) are expected to own ~1.8% of the combined company, pre‑closing Obsidian stockholders ~53.2%, and private placement investors ~45.0%. The transaction is subject to customary closing conditions and stockholder approvals and is expected to close by Q3 2026.
Galera Therapeutics announced a merger agreement with Obsidian Therapeutics concurrent with a committed $350M PIPE financing to advance OBX-115 development. The combined company will operate as Obsidian Therapeutics, with Madan Jagasia remaining CEO. Galera and the newly-formed company will file a registration statement on Form S-4 that will include a proxy statement and prospectus. The communication states the parties expect the transaction to close by Q3 2026 and directs investors to read the forthcoming Prospectus and SEC filings for details.
Galera Therapeutics and Obsidian Therapeutics announced a merger to take Obsidian public via a Nasdaq listing under the ticker OBX. The transaction includes a committed private placement of approximately $350M to support clinical milestones, and is expected to close by Q3 2026, subject to customary closing conditions.
The pre-closing ownership mix is described as approximately 53.2% for pre-closing Obsidian stockholders, 45.0% for private placement investors, and about 1.8% for pre-closing Galera stockholders, subject to adjustment based on Galera’s net cash immediately prior to closing. Obsidian’s executive team will continue to lead the combined company, which will operate under the name Obsidian Therapeutics.
Galera Therapeutics, Inc. disclosed a proposed business combination with Obsidian Therapeutics and stated the parties and a newly-formed company will file a registration statement on Form S-4 that will include a proxy statement/information statement and prospectus relating to the proposed transaction.
The communication warns that the Prospectus and other SEC filings will contain important information, notes that Galera and Obsidian executives may be participants in the solicitation, and cautions that forward-looking statements about the merger, planned clinical activities, milestone payments and a concurrent private placement financing are subject to risks described in Galera’s annual report.
Galera Therapeutics, Inc. entered into an Agreement and Plan of Merger with Obsidian Therapeutics and newly formed Parent (Gazelle Parent, Inc.) to combine the companies and create a Nasdaq-listed combined company. The transaction contemplates a $350.0 million Concurrent PIPE Financing, issuance of Parent common stock to Galera and Obsidian equityholders, and a Contingent Value Right (CVR) for Galera stockholders tied to proceeds from specified asset dispositions. At closing, pro forma ownership is expected to be approximately 53.2% pre-merger Obsidian equityholders, 45.0% PIPE Investors and 1.8% pre-merger Galera equityholders (assuming $350.0 million PIPE and a Galera valuation of $13.8 million). Closing is subject to stockholder approvals, Form S-4 effectiveness, listing on Nasdaq, receipt of PIPE proceeds and customary conditions. The Merger Agreement includes support and lock-up agreements, mutual representations and customary termination fees and covenants, and creates CVRs that may pay if specified proceeds are received.